by Madaline Spencer | Mar 28, 2025
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for rivoceranib plus camrelizumab to treat unresectable hepatocellular carcinoma (HCC). HCC is a rare liver cancer characterized by nodules composed of neoplastic epithelial cells...
by Madaline Spencer | Mar 28, 2025
Generalized pustular psoriasis (GPP) is a rare, severe form of psoriasis characterized by sterile pustules across large areas of skin. The condition most commonly affects individuals between the ages of 40 and 59 years. GPP may occur alongside plaque psoriasis and...
by Madaline Spencer | Mar 27, 2025
A recent study illustrated clinical improvements in patients with retinal dystrophy treated with gene therapy. Retinal dystrophy is a rare ophthalmology condition caused by a genetic deficiency of AIPL1. The condition is characterized by severe and rapid progression...
by Madaline Spencer | Mar 26, 2025
Takayuki Shirakawa, PhD, Research Scientist at Mitsubishi Tanabe Pharma, discusses the effects of LRSAM1 on TDP-43 in patients with amyotrophic lateral sclerosis (ALS). ALS, also referred to as “Lou Gehrig’s disease,” is a motor neuron disease...
by Madaline Spencer | Mar 25, 2025
The U.S. Food and Drug Administration has approved Fabhalta (iptacopan) for the treatment of C3 glomerulopathy (C3G) in adults. C3G is a rare kidney disease characterized by damage to kidney glomeruli due to abnormal activation of the complement system. When C3...
